Why insulin demand is hard to reduce
Insulin is not an optional purchase for people whose bodies cannot make enough of it: going without can cause severe illness and, in some cases, become life-threatening. That makes demand relatively inelastic—a price increase does not quickly make patients need less of the medicine. A shopper can postpone buying a different brand of cereal; a patient generally cannot safely postpone insulin in the same way.
But “need” does not mean people can pay any price. When costs exceed what they can afford, some patients ration doses or skip them, with dangerous consequences. The market’s apparent resilience to higher prices can therefore conceal real harm rather than prove that price does not matter.
The price on the label is not the whole price
In the United States, insulin often moves through a chain involving manufacturers, wholesalers, insurers, and pharmacy benefit managers—companies that negotiate drug coverage and payments for health plans. Manufacturers set list prices, while rebates and other negotiated discounts can make the amount ultimately retained different. The patient’s bill may depend on insurance terms, such as whether cost-sharing is calculated from the list price or a discounted amount.
That separation can weaken the usual shopping signal. The person who needs insulin may not choose among products based only on price, may face limits on which products an insurer covers, and may find switching difficult because treatment must remain safe and effective. Meanwhile, the party negotiating a discount is not necessarily the patient paying at the pharmacy counter.
Why competition may not quickly fix the problem
A lower-priced alternative can help only if it is available, covered, and suitable for the patient. Insulin products are not always interchangeable in practice: changing a formulation or delivery device can require clinical guidance and adjustments. These constraints make it harder for patients to respond to a price increase by simply choosing a substitute.
The result is a market where need is steady but bargaining power is divided among several players. A high price may not immediately drive patients away; instead, it can show up in insurance costs, out-of-pocket bills, or the painful choice to use less than prescribed.
